Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters

Inflammopharmacology

Volumn 22, Issue 5, 2014, Pages 295-303

  Sexton, Michelle ^a,b   Cudaback, Eiron ^c   Abdullah, Rehab A ^d   Finnell, John ^e   Mischley, Laurie K ^b   Rozga, Mary ^f   Lichtman, Aron H ^d   Stella, Nephi ^c,g  

^a Center for the Study of Cannabis and Social Policy   (United States)

^b BASTYR UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e AOMA Graduate School of Integrative Medicine   (United States)

^f MICHIGAN STATE UNIVERSITY   (United States)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Cannabis; Case control study; Cytokines; Endocannabinoids; Inflammation; Monocytes; Multiple sclerosis

Indexed keywords

AMIDE; ANANDAMIDE; ARACHIDONIC ACID DERIVATIVE; CANNABINOID; CANNABIS; CCL2 PROTEIN, HUMAN; ENDOCANNABINOID; INTERLEUKIN 17; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; BLOOD; CANNABIS SMOKING; CASE CONTROL STUDY; CELL MOTION; CHEMISTRY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MONOCYTE; MULTIPLE SCLEROSIS; PHYSIOLOGY;

ADULT; ARACHIDONIC ACIDS; CANNABINOIDS; CANNABIS; CASE-CONTROL STUDIES; CELL MOVEMENT; CHEMOKINE CCL2; CROSS-SECTIONAL STUDIES; ENDOCANNABINOIDS; FEMALE; HUMANS; INTERLEUKIN-17; MALE; MARIJUANA SMOKING; MONOCYTES; MULTIPLE SCLEROSIS; POLYUNSATURATED ALKAMIDES;

EID: 84929997681     PISSN: 09254692     EISSN: 15685608     Source Type: Journal    
DOI: 10.1007/s10787-014-0214-z     Document Type: Article

References (72)

1. Abood ME, Sorenson RG, Stella N (2013) Endocannabinoids: actions at non CB1/CB2 receptors. Springer, New York
2. Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, Naves R, Han M, Zhong F, Castellanos JG, Mair R, Christakos A, Kolkowitz I, Katz L, Killestein J, Polman CH, de Waal Malefyt R, Steinman L, Raman C (2010) T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 16(4):406–412
3. Boven LA, Van Meurs M, Van Zwam M, Wierenga-Wolf A, Hintzen RQ, Boot RG, Aerts JM, Amor S, Nieuwenhuis EE, Laman JD (2006) Myelin-laden macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis. Brain 129(Pt 2):517–526
4. Broseus J, Anglada F, Esseiva P (2010) The differentiation of fibre- and drug type Cannabis seedlings by gas chromatography/mass spectrometry and chemometric tools. Forensic Sci Int 200(1–3):87–92
5. Caraceni P, Viola A, Piscitelli F, Giannone F, Berzigotti A, Cescon M, Domenicali M, Petrosino S, Giampalma E, Riili A, Grazi G, Golfieri R, Zoli M, Bernardi M, Di Marzo V (2010) Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. Liver Int 30(6):816–825
6. Chen SJ, Wang YL, Fan HC, Lo WT, Wang CC, Sytwu HK (2012) Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis. Clin Dev Immunol 2012:970789
7. Clark AJ, Ware MA, Yazer E, Murray TJ, Lynch ME (2004) Patterns of cannabis use among patients with multiple sclerosis. Neurology 62(11):2098–2100
8. Conductier GN, Blondeau A, Guyon JL, Nahon, Rovere C (2010) The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J Neuroimmunol 224(1–2):93–100
9. Correa FG, Mestre L, Docagne F, Borrell J, Guaza C (2009) The endocannabinoid anandamide from immunomodulation to neuroprotection. Implications for multiple sclerosis. Vitam Horm 81:207–230
10. De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V (2003) Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis 2:5
11. De Santo C, Salio M, Masri SH, Lee LY, Dong T, Speak AO, Porubsky S, Booth S, Veerapen N, Besra GS, Grone HJ, Platt FM, Zambon M, Cerundolo V (2008) Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J Clin Invest 118(12):4036–4048
12. Downer EJ (2011) Cannabinoids and innate immunity: taking a toll on neuroinflammation. Sci World J 11:855–865
13. Eljaschewitsch E, Witting A, Mawrin C, Lee T, Schmidt PM, Wolf S, Hoertnagl H, Raine CS, Schneider-Stock R, Nitsch R, Ullrich O (2006) The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 49(1):67–79
14. ElSohly MA (ed) (2007) Forensic science and medicine: marijuana and the cannabinoids. Humana Press Inc., Totowa
15. Felder CC, Glass M (1998) Cannabinoid receptors and their endogenous agonists. Annu Rev Pharmacol Toxicol 38:179–200
16. Frisullo G, Nociti V, Iorio R, Patanella AK, Marti A, Caggiula M, Mirabella M, Tonali PA, Batocchi AP (2008) IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis. Cytokine 44(1):22–25
17. Gaoni YMR (1964) Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86(8):1646–1647
18. Hecker M, Paap BK, Goertsches RH, Kandulski O, Fatum C, Koczan D, Hartung HP, Thiesen HJ, Zettl UK (2011) Reassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosis. PLoS One 6(12):e29648
19. Hegde VL, Nagarkatti M, Nagarkatti PS (2010) Cannabinoid receptor activation leads to massive mobilization of myeloid-derived suppressor cells with potent immunosuppressive properties. Eur J Immunol 40(12):3358–3371
20. Hegde VL, Nagarkatti PS, Nagarkatti M (2011) Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol. PLoS One 6(4):e18281
21. Hill MN, Miller GE, Carrier EJ, Gorzalka BB, Hillard CJ (2009) Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology 34(8):1257–1262
22. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54(2):161–202
23. Jackson SJ, Pryce G, Diemel LT, Cuzner ML, Baker D (2005) Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation. Neuroscience 134(1):261–268
24. Jean-Gilles L, Feng S, Tench CR, Chapman V, Kendall DA, Barrett DA, Constantinescu CS (2009) Plasma endocannabinoid levels in multiple sclerosis. J Neurol Sci 287(1–2):212–215
25. Kallaur AP, Oliveira SR, Colado Simao AN, Delicato de Almeida ER, Kaminami Morimoto H, Lopes J, de Carvalho Jennings Pereira WL, Marques Andrade R, Muliterno Pelegrino L, Donizete Borelli S, Kaimen-Maciel DR, Reiche EM (2013) Cytokine profile in relapsingremitting multiple sclerosis patients and the association between progression and activity of the disease. Mol Med Rep 7(3):1010–1020
26. Katona S, Kaminski E, Sanders H, Zajicek J (2005) Cannabinoid influence on cytokine profile in multiple sclerosis. Clin Exp Immunol 140(3):580–585
27. Kennedy KJ, Karpus WJ (1999) Role of chemokines in the regulation of Th1/Th2 and autoimmune encephalomyelitis. J Clin Immunol 19(5):273–279
28. Killestein J, Hoogervorst EL, Reif M, Blauw B, Smits M, Uitdehaag BM, Nagelkerken L, Polman CH (2003) Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis. J Neuroimmunol 137(1–2):140–143
29. Klein TW (2005) Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5(5):400–411
30. Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L, Friedman H (2003). The cannabinoid system and immune modulation. J Leukoc Biol 74:486–496
31. Koppel J, Bradshaw H, Goldberg TE, Khalili H, Marambaud P, Walker MJ, Pazos M, Gordon ML, Christen E, Davies P (2009) Endocannabinoids in Alzheimer’s disease and their impact on normative cognitive performance: a case-control and cohort study. Lipids Health Dis 8:2
32. Kouwenhoven M, Teleshova N, Ozenci V, Press R, Link H (2001) Monocytes in multiple sclerosis: phenotype and cytokine profile. J Neuroimmunol 112(1–2):197–205
33. Kozela E, Juknat A, Kaushansky N, Rimmerman N, Ben-Nun A, Vogel Z (2013) Cannabinoids decrease the Th17 inflammatory autoimmune phenotype. J Neuroimmune Pharmacol 8(5):1265–1276
34. Kuerten S, Lehmann PV (2011) The immune pathogenesis of experimental autoimmune encephalitis: lessons learned for multiple sclerosis? J Interf Cytokine Res 12(31):907–916
35. Li Y, Wang H, Long Y, Lu Z, Hu X (2011) Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis. J Neuroimmunol 234(1–2):155–160
36. Mackie K, Stella N (2006) Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J 8(2):E298–E306
37. Mameli G, Poddighe L, Mei A, Uleri E, Sotgiu S, Serra C, Manetti R, Dolei A (2012) Expression and activation by epstein barr virus of human endogenous retroviruses-w in blood cells and astrocytes: inference for multiple sclerosis. PLoS One 7(9):e44991
38. Martinez-Rodriguez JE, Munteis E, Carreno M, Blanco Y, Roquer J, Abanades S, Graus F, Saiz A (2008) Cannabis use in Spanish patients with multiple sclerosis: fulfilment of patients’ expectations? J Neurol Sci 273(1–2):103–107
39. Massi P, Fuzio D, Vigano D, Sacerdote P, Parolaro D (2000) Relative involvement of cannabinoid CB(1) and CB(2) receptors in the Delta(9)-tetrahydrocannabinol-induced inhibition of natural killer activity. Eur J Pharmacol 387(3):343–347
40. Matias I, Gatta-Cherifi B, Tabarin A, Clark S, Leste-Lasserre T, Marsicano G, Piazza PV, Cota D (2012) Endocannabinoids measurement in human saliva as potential biomarker of obesity. PLoS One 7(7):e42399
41. McCoy L, Tsunoda I, Fujinami RS (2006) Multiple sclerosis and virus induced immune responses: autoimmunity can be primed by molecular mimicry and augmented by bystander activation. Autoimmunity 39(1):9–19
42. Mikita J, Dubourdieu-Cassagno N, Deloire MS, Vekris A, Biran M, Raffard G, Brochet B, Canron MH, Franconi JM, Boiziau C, Petry KG (2011) Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration. Mult Scler 17(1):2–15
43. Miller AM, Stella N (2009) Microglial cell migration stimulated by ATP and C5a involve distinct molecular mechanisms: quantification of migration by a novel near-infrared method. Glia 57(8):875–883
44. Murray PJ, Wynn TA (2011) Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 11(11):723–737
45. Nahas GG, Suciu-Foca N, Armand JP, Morishima A (1974) Inhibition of cellular mediated immunity in marihuana smokers. Science 183(4123):419–420
46. Nahas GG, Morishima A, Desoize B (1977) Effects of cannabinoids on macromolecular synthesis and replication of cultured lymphocytes. Fed Proc 36(5):1748–1752
47. Newton CA, Klein TW, Friedman H (1994) Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection. Infect Immun 62(9):4015–4020
48. Nong L, Newton C, Cheng Q, Friedman H, Roth MD, Klein TW (2002) Altered cannabinoid receptor mRNA expression in peripheral blood mononuclear cells from marijuana smokers. J Neuroimmunol 127(1–2):169–176
49. Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R (2012) A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex(R) (nabiximols). Mult Scler 18(2):219–228
50. Oreja-Guevara C, Ramos-Cejudo J, Stark Aroeira L, Chamorro B, Diez-Tejedor E (2012) TH1/TH2 cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab. BMC Neurol 12(1):95
51. Pacifici R, Zuccaro P, Pichini S, Roset PN, Poudevida S, Farre M, Segura J, De la Torre R (2003) Modulation of the immune system in cannabis users. JAMA 289(15):1929–1931
52. Pacifici R, Zuccaro P, Farre M, Poudevida S, Abanades S, Pichini S, Langohr K, Segura J, de la Torre R (2007) Combined immunomodulating properties of 3,4-methylenedioxymethamphetamine (MDMA) and cannabis in humans. Addiction 102(6):931–936
53. Palazuelos J, Davoust N, Julien B, Hatterer E, Aguado T, Mechoulam R, Benito C, Romero J, Silva A, Guzman M, Nataf S, Galve-Roperh I (2008) The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J Biol Chem 283(19):13320–13329
54. Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74(2):129–180
55. Pertwee RG (2002) Cannabinoids and multiple sclerosis. Pharmacol Ther 95(2):165–174
56. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacol Rev 62(4):588–631
57. Pini A, Mannaioni G, Pellegrini-Giampietro D, Passani MB, Mastroianni R, Bani D, Masini E (2012) The role of cannabinoids in inflammatory modulation of allergic respiratory disorders, inflammatory pain and ischemic stroke. Curr Drug Targets 13(7):984–993
58. Pryce G, Baker D (2007) Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br J Pharmacol 150(4):519–525
59. Pryce G, Baker D (2012) Potential control of multiple sclerosis by cannabis and the endocannabinoid system. CNS Neurol Disord Drug Targets 11:624–621
60. Ramesh D, Ross GR, Schlosburg JE, Owens RA, Abdullah RA, Kinsey SG, Long JZ, Nomura DK, Sim-Selley LJ, Cravatt BF, Akbarali HI, Lichtman AH (2011) Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice. J Pharmacol Exp Ther 339(1):173–185
61. Rog DJ, Nurmikko TJ, Young CA (2007) Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther 29(9):2068–2079
62. Russo EB (2007) History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers 4(8):1614–1648
63. Sastre-Garriga J, Vila C, Clissold S, Montalban X (2011) THC and CBD oromucosal spray (Sativex(R)) in the management of spasticity associated with multiple sclerosis. Expert Rev Neurother 11(5):627–637
64. Sexton M, Silvestroni A, Moller T, Stella N (2012) Differential migratory properties of monocytes isolated from human subjects naive and non-naive to cannabis. Inflammopharmacology 21(3):253–259
65. Shechter R, Schwartz M (2012) Harnessing monocyte-derived macrophages to control central nervous system pathologies: no longer ‘if’ but ‘how’. J Pathol 229(2):332–346
66. Simmons A (2001) Herpesvirus and multiple sclerosis. Herpes 8(3):60–63
67. Smith SR, Terminelli C, Denhardt G (2000) Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J Pharmacol Exp Ther 293(1):136–150
68. Stella N (2010) Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58(9):1017–1030
69. Tanasescu R, Constantinescu CS (2010) Cannabinoids and the immune system: an overview. Immunobiology 215(8):588–597
70. Wade DT, Collin C, Stott C, Duncombe P (2010) Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 16(6):707–714
71. Ware MA, Adams H, Guy GW (2005) The medicinal use of cannabis in the UK: results of a nationwide survey. Int J Clin Pract 59(3):291–295
72. Zhao P, Abood ME (2012) GPR55 and GPR35 and their relationship to cannabinoid and lysophospholipid receptors. Life Sci